Abstract:The developmental and epileptic encephalopathies encompass a group of rare syndromes characterised by severe drug-resistant epilepsy with onset in childhood and significant neurodevelopmental comorbidities. The latter include intellectual disability, developmental delay, behavioural problems including attention-deficit hyperactivity disorder and autism spectrum disorder, psychiatric problems including anxiety and depression, speech impairment and sleep problems. Classical examples of developmental and epileptic encephalopathies include Dravet syndrome, Lennox–Gastaut syndrome and tuberous sclerosis complex. The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep. We have performed a targeted literature review of ASMs commonly used in the treatment of developmental and epileptic encephalopathies to discuss the latest evidence on their effects on behaviour, mood, cognition, sedation and sleep. The ASMs include valproate (VPA), clobazam, topiramate (TPM), cannabidiol (CBD), fenfluramine (FFA), levetiracetam (LEV), brivaracetam (BRV), zonisamide (ZNS), perampanel (PER), ethosuximide, stiripentol, lamotrigine (LTG), rufinamide, vigabatrin, lacosamide (LCM) and everolimus. Bromide, felbamate and other sodium channel ASMs are discussed briefly. Overall, the current evidence suggest that LEV, PER and to a lesser extent BRV are associated with psychobehavioural adverse events including aggressiveness and irritability; TPM and to a lesser extent ZNS are associated with language impairment and cognitive dulling/memory problems. Patients with a history of behavioural and psychiatric comorbidities may be more at risk of developing psychobehavioural adverse events. Topiramate and ZNS may be associated with negative effects in some aspects of cognition; CBD, FFA, LEV, BRV and LTG may have some positive effects, while the remaining ASMs do not appear to have a detrimental effect. All the ASMs are associated with sedation to a certain extent, which is pronounced during uptitration. Cannabidiol, PER and pregabalin may be associated with improvements in sleep, LTG is associated with insomnia, while VPA, TPM, LEV, ZNS and LCM do not appear to have detrimental effects. There was variability in the extent of evidence for each ASM: for many first-generation and some second-generation ASMs, there is scant documented evidence; however, their extensive use suggests favourable tolerability and safety (e.g. VPA); second-generation and some third-generation ASMs tend to have the most robust evidence documented over several years of use (TPM, LEV, PER, ZNS, BRV), while evidence is still being generated for newer ASMs such as CBD and FFA. Finally, we discuss how a variety of factors can affect mood, behaviour and cognition, and untangling the associations between the effects of the underlying syndrome and those of the ASMs can be challenging. In particular, there is enormous heterogeneity in cognitive, behavioural and developmental impairments that is complex and can change naturally over time; there is a lack of standardised instruments for evaluating these outcomes in developmental and epileptic encephalopathies, with a reliance on subjective evaluations by proxy (caregivers); and treatment regimes are complex involving multiple ASMs as well as other drugs.

Benzodiazepines for pediatric epilepsies and their risks in a cohort within the French health care data

Trends of Anti-Seizure Medication Use in Pediatric Patients in Six Cities in China from 2013 to 2018

Anti-seizure Medication Prescription in Adult Outpatients with Epilepsy in China, 2013–2018

Changes in the use of antiseizure medications in children and adolescents in Norway, 2009-2018

Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020

Benzodiazepine administration patterns before escalation to second-line medications in pediatric refractory convulsive status epilepticus

Anti-Seizure Medication Treatment of Benign Childhood Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis

Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study

Retention Rates and Successful Treatment with Antiseizure Medications in Newly-Diagnosed Epilepsy Patients

Evaluation of drug safety in pediatric epileptic patients: A prospective interventional study with clinical pharmacist intervention at a tertiary care teaching hospital

Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis

National assessment of anti-epileptic drug exposures among pre-teens and adolescents, 2000-2020

The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy

Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs

Profile of Chronic Non-Epilepsy Drug Use in Children with Epilepsy: Single Centre Experience

Teratogenicity Rates in Nearly 10 000 Offsprings of Antiseizure Medication-Exposed Pregnancies

Evaluation of Levetiracetam and Valproic Acid As Low-Dose Monotherapies for Children with Typical Benign Childhood Epilepsy with Centrotemporal Spikes (BECTS).

First-line medication dosing in pediatric refractory status epilepticus

Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies

Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy